deltatrials
Completed PHASE4 INTERVENTIONAL 1-arm NCT05219162

Real-World Study on Gene Profile in Patients With Advanced NSCLC Who Progressed on First-Line Osimertinib Therapy(GPS). (GPS)

Gene Profile in EGFRm Locally Advanced or Metastatic NSCLC Patients Post Osimertinib 1L Treatment Failure: A Real-world, Multi-center Study (GPS)

Sponsor: AstraZeneca

Conditions Advanced NSCLC
Interventions Gene Profile explore
Updated 28 times since 2022 Last updated: Aug 26, 2025 Started: Feb 25, 2022 Primary completion: Apr 29, 2024 Completion: Apr 29, 2024
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT05219162, this PHASE4 trial focuses on Advanced NSCLC and remains completed. Sponsored by AstraZeneca, it has been updated 28 times since 2022, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

~Feb 2022 – ~Apr 2022 · 59 days · monthly snapshot~Apr 2022 – ~May 2022 · 30 days · monthly snapshot~May 2022 – ~Jun 2022 · 31 days · monthly snapshot~Jun 2022 – ~Jul 2022 · 30 days · monthly snapshot~Jul 2022 – ~Sep 2022 · 2 months · monthly snapshot~Sep 2022 – ~Nov 2022 · 2 months · monthly snapshot~Nov 2022 – ~Dec 2022 · 30 days · monthly snapshot~Dec 2022 – ~Jan 2023 · 31 days · monthly snapshot~Jan 2023 – ~Feb 2023 · 31 days · monthly snapshot~Feb 2023 – ~Mar 2023 · 28 days · monthly snapshot~Mar 2023 – ~Apr 2023 · 31 days · monthly snapshot~Apr 2023 – ~May 2023 · 30 days · monthly snapshot~May 2023 – ~Jun 2023 · 31 days · monthly snapshot~Jun 2023 – ~Jul 2023 · 30 days · monthly snapshot~Jul 2023 – ~Aug 2023 · 31 days · monthly snapshot~Aug 2023 – ~Sep 2023 · 31 days · monthly snapshot~Sep 2023 – ~Oct 2023 · 30 days · monthly snapshot~Oct 2023 – ~Nov 2023 · 31 days · monthly snapshot~Nov 2023 – ~Dec 2023 · 30 days · monthly snapshot~Dec 2023 – ~Jan 2024 · 31 days · monthly snapshot~Jan 2024 – ~Feb 2024 · 31 days · monthly snapshot~Feb 2024 – ~Apr 2024 · 2 months · monthly snapshot~Apr 2024 – ~May 2024 · 30 days · monthly snapshot~May 2024 – ~Jun 2024 · 31 days · monthly snapshot~Jun 2024 – ~Jul 2024 · 30 days · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Oct 2025 · 13 months · monthly snapshot~Oct 2025 – present · 10 months · monthly snapshot

Change History

28 versions recorded

  1. Oct 2025 — Present [monthly]

    Completed PHASE4

  2. Sep 2024 — Oct 2025 [monthly]

    Completed PHASE4

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE4

  4. Jun 2024 — Jul 2024 [monthly]

    Completed PHASE4

    Status: Recruiting → Completed

  5. May 2024 — Jun 2024 [monthly]

    Recruiting PHASE4

▶ Show 23 earlier versions

  1. Apr 2024 — May 2024 [monthly]

    Recruiting PHASE4

  2. Feb 2024 — Apr 2024 [monthly]

    Recruiting PHASE4

  3. Jan 2024 — Feb 2024 [monthly]

    Recruiting PHASE4

  4. Dec 2023 — Jan 2024 [monthly]

    Recruiting PHASE4

  5. Nov 2023 — Dec 2023 [monthly]

    Recruiting PHASE4

  6. Oct 2023 — Nov 2023 [monthly]

    Recruiting PHASE4

  7. Sep 2023 — Oct 2023 [monthly]

    Recruiting PHASE4

  8. Aug 2023 — Sep 2023 [monthly]

    Recruiting PHASE4

  9. Jul 2023 — Aug 2023 [monthly]

    Recruiting PHASE4

  10. Jun 2023 — Jul 2023 [monthly]

    Recruiting PHASE4

  11. May 2023 — Jun 2023 [monthly]

    Recruiting PHASE4

  12. Apr 2023 — May 2023 [monthly]

    Recruiting PHASE4

  13. Mar 2023 — Apr 2023 [monthly]

    Recruiting PHASE4

  14. Feb 2023 — Mar 2023 [monthly]

    Recruiting PHASE4

  15. Jan 2023 — Feb 2023 [monthly]

    Recruiting PHASE4

  16. Dec 2022 — Jan 2023 [monthly]

    Recruiting PHASE4

  17. Nov 2022 — Dec 2022 [monthly]

    Recruiting PHASE4

  18. Sep 2022 — Nov 2022 [monthly]

    Recruiting PHASE4

  19. Jul 2022 — Sep 2022 [monthly]

    Recruiting PHASE4

  20. Jun 2022 — Jul 2022 [monthly]

    Recruiting PHASE4

  21. May 2022 — Jun 2022 [monthly]

    Recruiting PHASE4

  22. Apr 2022 — May 2022 [monthly]

    Recruiting PHASE4

    Status: Not Yet Recruiting → Recruiting

  23. Feb 2022 — Apr 2022 [monthly]

    Not Yet Recruiting PHASE4

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • AstraZeneca
Data source: AstraZeneca

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Beijing, China , Changsha, China , Chengdu, China , Dalian, China , Foshan, China , Fuzhou, China , Harbin, China , Hefei, China , Linhai, China , Luoyang, China and 5 more locations